Somatuline Predictive Factors in Acromegaly and NET

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

156 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictive Factors Study

NCT02020499

Acromegaly

TERMINATED

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

NCT00447499

Acromegaly

COMPLETED PHASE3

Non Interventional Post Marketing Programme in Acromegaly

NCT00747500

Acromegaly

COMPLETED

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

NCT00517491

Acromegaly

WITHDRAWN PHASE2

Somatuline Autogel: Acromegaly Self/Partner Injection Study

NCT00149188

Acromegaly

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acromegaly Neuroendocrine Tumours

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neuroendocrine Tumours

The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.

Somatuline Autogel® 60, 90 or 120 mg

Intervention Type DRUG

Acromegaly

The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.

Somatuline Autogel® 60, 90 or 120 mg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Somatuline Autogel® 60, 90 or 120 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent (also mandatory in case of retrospective documentation of subject data)
* Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG